Relationship between thrombophilic disorders and type of severe early-onset hypertensive disorder of pregnancy

Hypertension in Pregnancy

Volumn 26, Issue 4, 2007, Pages 433-445

  Ganzevoort, Wessel ^a   Rep, Annelies ^b   De Vries, Johanna Ip ^b   Bonsel, Gouke J ^b   Wolf, Hans ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Fetal growth restriction; HELLP syndrome; Preeclampsia; Thrombophilia

Indexed keywords

CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; METHIONINE; PHOSPHOLIPID ANTIBODY;

ADULT; APC PROTEIN MUTATION; ARTICLE; BIRTH WEIGHT; BLOOD CLOTTING FACTOR 5 LEIDEN MUTATION; BODY MASS; CARDIOVASCULAR SYSTEM; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ECLAMPSIA; FAMILY HISTORY; FEMALE; GENETIC DISORDER; HELLP SYNDROME; HUMAN; HYPERHOMOCYSTEINEMIA; INTRAUTERINE GROWTH RETARDATION; MATERNAL HYPERTENSION; MORBIDITY; NETHERLANDS; OUTCOME ASSESSMENT; PREECLAMPSIA; PREVALENCE; PROTEIN S DEFICIENCY; PROTHROMBIN MUTATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SCREENING TEST; SMOKING; STATISTICAL ANALYSIS; THROMBOPHILIA; UNIVARIATE ANALYSIS; UNIVERSITY HOSPITAL;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; BIRTH WEIGHT; BODY MASS INDEX; COHORT STUDIES; ECLAMPSIA; FACTOR V; FEMALE; FETAL GROWTH RETARDATION; FOLLOW-UP STUDIES; HELLP SYNDROME; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION, PREGNANCY-INDUCED; INFANT, NEWBORN; LUPUS COAGULATION INHIBITOR; MUTATION; POINT MUTATION; PRE-ECLAMPSIA; PREGNANCY; PROTEIN S DEFICIENCY; PROTHROMBIN; SMOKING; THROMBOPHILIA;

EID: 36849077283     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.1080/10641950701521601     Document Type: Article

References (48)

1. Sibai BM. Prevention of preeclampsia: a big disappointment. Am J Obstet Gynecol 1998; 179(5):1275-1278.
2. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180(2 Pt 1):499-506.
3. Harlow FH, Brown MA. The diversity of diagnoses of preeclampsia. Hypertens Pregnancy 2001; 20(1):57-67.
4. Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing? Am J Obstet Gynecol 1990; 162(2):311-316.
5. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988; 158(4):892-898.
6. Gardosi J, Chang A, Kalyan B, Sahota D, Symonds EM. Customised antenatal growth charts. Lancet 1992; 339(8788):283-287.
7. Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body, and femur measurements - a prospective study. Am J Obstet Gynecol 1985; 151(3):333-337.
8. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340(1):9-13.
9. Rigo J, Jr., Nagy B, Fintor L, Tanyi J, Beke A, Karadi I, et al. Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase. Hypertens Pregnancy 2000; 19(2):163-172.
10. von Tempelhoff GF, Heilmann L, Spanuth E, Kunzmann E, Hommel G. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP-syndrome. Hemolysis, elevated liver-enzymes, low platelets. Thromb Res 2000; 100(4):363-365.
11. Van Pampus MG, Dekker GA, Wolf H, Huijgens PC, Koopman MM, Blomberg BM, et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999; 180(5):1146-1150.
12. Benedetto C, Marozio L, Salton L, Maula V, Chieppa G, Massobrio M. Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome. Acta Obstet Gynecol Scand 2002; 81(12):1095-1100.
13. Schlembach D, Beinder E, Zingsem J, Wunsiedler U, Beckmann MW, Fischer T. Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth restriction. Clin Sci (Colch ) 2003; 105(3):279-285.
14. Kupferminc MJ, Fait G, Many A, Gordon D, Eldor A, Lessing JB. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol 2000; 96(1):45-49.
15. Dekker GA, De Vries JI, Doelitzsch PM, Huijgens PC, Von Blomberg BM, Jakobs C, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995; 173(4):1042-8.
16. Kupferminc MJ, Rimon E, Ascher-Landsberg J, Lessing JB, Many A. Perinatal outcome in women with severe pregnancy complications and multiple thrombophilias. J Perinat Med 2004; 32(3):225-227.
17. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175(4 Pt 1):902-905.
18. Nagy B, Toth T, Rigo J, Jr., Karadi I, Romics L, Papp Z. Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women. Clini Genet 1998; 53(6):478-481.
19. Krauss T, Augustin HG, Osmers R, Meden H, Unterhalt M, Kuhn W. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol 1998; 92(3):457-460.
20. Kupferminc MJ, Peri H, Zwang E, Yaron Y, Wolman I, Eldor A. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss. Acta Obstet Gynecol Scand 2000; 79(11):963-967.
21. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Euro J Obstet, Gynecol Reprod Biol 2002; 101(1):6-14.
22. Kupferminc MJ, Many A, Bar-Am A, Lessing JB, Ascher-Landsberg J. Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. Br J Obstet Gynaecol 2002; 109(12):1373-1376.
23. Martinelli P, Grandone E, Colaizzo D, Paladini D, Scianname N, Margaglione M, et al. Familial thrombophilia and the occurrence of fetal growth restriction. Haematologica 2001; 86(4):428-431.
24. Verspyck E, Cam-Duchez V, Goffinet F, Tron F, Marpeau L, Borg JY. Thrombophilia and immunological disorders in pregnancies as risk factors for small for gestational age infants. Br J Obstet Gynaecol 2002; 109(1):28-33.
25. Ganzevoort W, Rep A, Bonsel GJ, De Vries JI, Wolf H. A randomized trial of plasma volume expansion in hypertensive disorders of pregnancy: influence on the pulsatility indices of the fetal umbilical artery and middle cerebral artery. Am J Obstet Gynecol 2005; 192(1):233-239.
26. Ganzevoort W, Rep A, Bonsel GJ, Fetter WPF, van Sonderen L, de Vries JIP, et al. A randomised controlled trial comparing a temporising management strategy with plasma volume expansion with one without plasma volume expansion. Br J Obstet Gynaecol 2005; 112:1358-1368.
27. Giri TK, Hillarp A, Hardig Y, Zoller B, Dahlback B. A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen. Thromb Haemost 1998; 79(4):767-772.
28. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90(3):1004-1008.
29. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994; 343(8912):1535-1536.
30. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3?-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88(10):3698-3703.
31. Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatog 1991; 565(1-2):441-446.
32. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74(4):1185-1190.
33. Harris EN. Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990; 94(4):476-484.
34. Infante-Rivard C, Rivard GE, Yotov WV, Genin E, Guiguet M, Weinberg C, et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 2002; 347(1):19-25.
35. Kim YJ, Williamson RA, Murray JC, Andrews J, Pietscher JJ, Peraud PJ, et al. Genetic susceptibility to preeclampsia: roles of cytosineto-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathionine beta-synthase, and factor V Leiden mutation. Am J Obstet Gynecol 2001; 184(6):1211-1217.
36. Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol 2001; 185(1):153-157.
37. Currie L, Peek M, McNiven M, Prosser I, Mansour J, Ridgway J. Is there an increased maternal-infant prevalence of Factor V Leiden in association with severe pre-eclampsia? Br J Obstet Gynaecol 2002; 109(2):191-196.
38. Morrison ER, Miedzybrodzka ZH, Campbell DM, Haites NE, Wilson BJ, Watson MS, et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002;87(5):779-785.
39. O'Shaughnessy KM, Fu B, Ferraro F, Lewis I, Downing S, Morris NH. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an East Anglian preeclampsia cohort. Hypertension 1999; 33(6):1338-1341.
40. De Groot CJ, Bloemenkamp KW, Duvekot EJ, Helmerhorst FM, Bertina RM, Van Der MF, et al. Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol 1999; 181(4):975-980.
41. Lin J, August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol 2005; 105(1):182-192.
42. Kosmas IP, Tatsioni A, Ioannidis JP. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 2003; 21(7):1221-1228.
43. Kosmas IP, Tatsioni A, Ioannidis JP. Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 2004; 22(9):1655-1662.
44. Pabinger I, Vormittag R. Thrombophilia and pregnancy outcomes. Journal of Thrombosis and Haemostasis 2005; 3(8):1603-1610.
45. Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res 2003; 109(2-3):73-81.
46. De Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, Van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997; 104(11):1248-1254.
47. Bodnar LM, Ness RB, Markovic N, Roberts JM. The risk of preeclampsia rises with increasing prepregnancy body mass index. Ann Epidemiol 2005; 15(7):475-482.
48. Ganzevoort W, Rep A, De Vries JI, Bonsel GJ, Wolf H, for the PETRA investigators. Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. Am J Obstet Gynecol 2006; 195(2):495-503.